Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
Status:
Completed
Trial end date:
2018-09-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of dapivirine
gel (0.05%) administered rectally to HIV-1 seronegative adults.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)